Automate Your Wheel Strategy on ATHA
With Tiblio's Option Bot, you can configure your own wheel strategy including ATHA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ATHA
- Rev/Share 0.0
- Book/Share 0.9561
- PB 0.3268
- Debt/Equity 0.0299
- CurrentRatio 7.2566
- ROIC -2.1523
- MktCap 12200750.0
- FreeCF/Share -2.2042
- PFCF -0.1418
- PE -0.153
- Debt/Assets 0.0257
- DivYield 0
- ROE -1.4299
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 5
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ATHA | Mizuho | Outperform | Neutral | $5 | $0.5 | Sept. 19, 2024 |
| Initiation | ATHA | Rodman & Renshaw | -- | Buy | -- | $22 | Aug. 19, 2024 |
News
Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit
ATHA
Published: May 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: May 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical development
Read More
About Athira Pharma, Inc. (ATHA)
- IPO Date 2020-09-18
- Website https://www.athira.com
- Industry Biotechnology
- CEO Dr. Mark J. Litton M.B.A., Ph.D.
- Employees 26
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.